Summary of significant nonhematologic adverse events on clinical trials with BTKi’s
| BTKi clinical trial . | Arthralgias, % . | Atrial fibrillation, % . | Bleeding/hemorrhage, % . | Hypertension, % . | Infection, % . |
|---|---|---|---|---|---|
| RESONATE-2: ibrutinib34 (N = 136) | 26 | 16 | 11 | 26 | 12* |
| A041202 | |||||
| Ibrutinib35 (n = 180) | 1 | 17 | 2* | 29* | 20* |
| Ibruitnib-rituximab35 (n = 181) | 2 | 14 | 4* | 34* | 20* |
| iLLUMINATE: Ibrutinib-Obintuzumab36 (N = 113) | 22 | 12 | NR | 17 | 14* |
| ECOG E1912: Ibrutinib-rituximab7 (N = 352) | 4.8* | 7.4 | NR | 18.8* | 9.4† |
| ELEVATE-TN | |||||
| Acalabrutinib40 (n = 179) | 11.2 | 3.9 | 1.7‡ | 4.5 | 14† |
| Acalabrutinib-obinutuzumab40 (n = 179) | 9.5 | 3.4 | 2.2‡ | 7.3 | 20.8† |
| BTKi clinical trial . | Arthralgias, % . | Atrial fibrillation, % . | Bleeding/hemorrhage, % . | Hypertension, % . | Infection, % . |
|---|---|---|---|---|---|
| RESONATE-2: ibrutinib34 (N = 136) | 26 | 16 | 11 | 26 | 12* |
| A041202 | |||||
| Ibrutinib35 (n = 180) | 1 | 17 | 2* | 29* | 20* |
| Ibruitnib-rituximab35 (n = 181) | 2 | 14 | 4* | 34* | 20* |
| iLLUMINATE: Ibrutinib-Obintuzumab36 (N = 113) | 22 | 12 | NR | 17 | 14* |
| ECOG E1912: Ibrutinib-rituximab7 (N = 352) | 4.8* | 7.4 | NR | 18.8* | 9.4† |
| ELEVATE-TN | |||||
| Acalabrutinib40 (n = 179) | 11.2 | 3.9 | 1.7‡ | 4.5 | 14† |
| Acalabrutinib-obinutuzumab40 (n = 179) | 9.5 | 3.4 | 2.2‡ | 7.3 | 20.8† |
All data are percentages.
NR, not reported.
Reported grade 3 or higher adverse event.
†Upper respiratory tract.
‡Grade 3 or any grade in central nervous system.